Liquid chromatography of tin-reduced technetium hydroxyethylidene diphosphonate complexes for on-line spectral characterization and double isotope labeling.
Liquid chromatography of tin-reduced technetium hydroxyethylidene diphosphonate complexes for on-line spectral characterization and double isotope labeling.
复制标题
用于在线光谱表征和双同位素标记的锡还原锝羟基亚乙基二膦酸盐络合物的液相色谱。
DOI：
10.1021/ac00297a006
复制
发表时间：
1986
影响因子：
7.4
通讯作者：
Pinkerton,TC
中科院分区：
文献类型：
--
作者：
Mikelsons,MV;Pinkerton,TC
建立了一种阴离子交换高效液相色谱分离方法，以毫摩尔浓度的锝-99分离锡还原的二磷酸羟乙基二磷酸锝配合物Tc-HEDP。这种分离有利于用二极管阵列分光光度计在线获取Tc-HEDP配合物的紫外可见光谱。设计了柱前反冲洗技术，用于每次进样后从色谱系统中去除未反应的高技术酸盐，从而防止随后含有Sn （II）的样品发生柱上反应。在pH为2.5、7.3和10.0的条件下制备Tc-HEDP配合物，以证明pH对配合物在分离内分布的影响。这些反应产生四到五种初级配合物，它们随ph值的变化而变化。大约有13种额外的复合物以微量的形式存在。用113Sn进行反应，以确定配合物中是否掺入了锡。只有一个小的配合物被发现含有锡。报道了10种Tc-HEDP配合物的紫外可见光谱特性。二膦酸锝在核医学领域被广泛用作骨成像放射性药物(1)。骨显像剂的合成包括用还原剂（如SnCl2， NaBH4等）在络合二膦酸盐配体（如二膦酸羟乙基乙烯（HEDP））存在下还原高技术酸盐（Tc04”）。
An anion-exchange high-performance liquid chromatographic separation has been developed for tin-reduced technetium hydroxyethylidene diphosphonate complexes, Tc-HEDP, at milllmolar concentrations of technetium-99. The separation facilitates the acquisition of ultraviolet-visible spectra of the Tc-HEDP complexes on-line with a diode array spectrophotometer. A precolumn backflush technique has been devised to remove unreacted pertechnetate from the chromatographic system after each injection, thus preventing on-column reac-tions from subsequent samples containing Sn (II). The Tc-HEDP complexes were prepared at pH 2.5, 7.3, and 10.0 to demonstrate the effect of pH on the distribution of complexes within the separation. The reactions produce from four to five primary complexes, which vary as a function ofpH. Some 13 additional complexes are present in trace amounts. The reactions were carried out with 113Sn to determine If tin is incorporated into the complexes. Only one minor complex was found to contain tin. The ultraviolet-visible spectral characteristics of 10 Tc-HEDP complexes are reported.Technetium diphosphonates are extensively employed as bone imaging radiopharmaceuticalsin the field of nuclear medicine (1). Synthesis of bone imaging agents involvesthe reduction of pertechnetate (Tc04 “) with a reductant (eg, SnCl2, NaBH4, etc.) in the presence of a complexing di-phosphonate ligand, such as hydroxyethylidene diphosphonate (HEDP).